ehp.124-A170

IL-23A/IL-23 P19 Antibody (473P19) Summary

    Immunogen
    The immunogen for this antibody was IL23 p19.
    Isotype
    IgG1 Kappa
    Clonality
    Monoclonal
    Host
    Mouse
    Gene
    IL23A
    Purity
    Protein A or G purified
    Innovators Reward
    Test in a species/application not listed above to receive a full credit towards a future purchase.

    Learn about the Innovators Reward

Applications/Dilutions

    Dilutions
        Western Blot 2 ug/ml
        ELISA 1:100-1:2000
    Application Notes
    The 473P19 antibody has been tested as the capture antibody in a sandwich ELISA for analysis of human IL-23 (p19p40) protein levels in combination with the biotinylated (p40-specific) C8.6 antibody (NBP1-48601B) for detection and recombinant human IL-23 (NBP1-48602) as the standard. A suitable range of concentrations of this antibody for ELISA capture is 2.5-8.0 ug/ml. A standard curve consisting of doubling dilutions of the recombinant IL-23 standard over the range of 2000 pg/ml – 15 pg/ml should be included in each ELISA plate. TMB, rather than ABTS, should be used as the substrate.The antibody 473p19 also works in immunoblotting under both reducing and nonreducing conditions at 2ug/ml.

Reactivity Notes

This antibody is reactive to Human.

Packaging, Storage & Formulations

    Storage
    Store at 4C. Do not freeze.
    Buffer
    Aqueous, may contain carrier protein/stabilizer.
    Preservative
    0.09% Sodium Azide
    Concentration
    0.5 mg/ml
    Purity
    Protein A or G purified

Alternate Names for IL-23A/IL-23 P19 Antibody (473P19)

      IL23
      IL-23
      IL23A
      IL-23A
      IL-23-A
      IL-23p19
      IL23P19P19
      interleukin 23 p19 subunit
      interleukin 23, alpha subunit p19
      interleukin-23 subunit alpha
      Interleukin-23 subunit p19
      JKA3 induced upon T-cell activation
      MGC79388
      SGRF
      SGRFIL-23 subunit alpha

Background

The 473P19 antibody reacts with the p19 subunit of human IL-23. The 473P19 antibody was generated from immunization with authentic, insect cell-expressed, recombinant human IL-23 heterodimer. The use of a p19-specific capture antibody and a p40-specific detection antibody yields a human IL-23 sandwich ELISA exquisitely specific for human IL-23. IL-12 p40 monomer and IL-12 p70 were run in the assay at 200 ng/ml with no interference or cross-reactivity observed. A panel of 20 unrelated cytokines was also run in the IL-23 ELISA at 100 ng/ml with no cross reactivity observed. The assay has been validated by specific detection of significant levels of native human IL-23 protein in supernatants from a variety of different activated dendritic cell populations. IL-23 is a heterodimeric cytokine composed of the p40 subunit of IL-12 disulfide-linked with a protein p19. p19, like p35 of IL-12, is biologically inactive by itself. IL-23 interacts with IL-12Rbeta1 and an additional, novel beta2-like receptor subunit with STAT4 binding domain, termed IL-23R. IL-23 is secreted by activated mouse and human dendritic cells. Biological activities of mouse IL-23 are distinct from those of mouse IL-12. Mouse IL-23 was found not to induce significant amounts of IFN-g. Mouse IL-23 does induce strong proliferation of memory T cells (but not nave T cells), whereas IL-12 has no effect on memory cells. Additionally, mouse IL-23 (but not IL-12) can activate mouse memory T cells to produce the proinflammatory cytokine IL-17. Human IL-23 has biological properties which are less distinct from human IL-12 human IL-23 induces proliferation of memory T cells and induces moderate levels of IFN-g production by nave and memory T cells, as compared to IL-12. IL-23-dependent, IL-17-producing CD4+ T cells (Th-17 cells) have been identified as a unique subset of Th cells that develops along a pathway that is distinct from the Th1- and Th2- cell differentiation pathways. The hallmark effector molecules of Th1 and Th2 cells, e.g., IFN-g and IL-4, have each been found to negatively regulate the generation of these Th-17 cells. More recently, de novo differentiation of Th-17 cells in the absence of IL-23 has been demonstrated by treatment of nave CD4 cells with TGF-beta1 and IL-6.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

GSK2126459

Related Post